15 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 19.3% per year over the past 5 years.
Net income has grown slower than revenue (8.8% vs 19.3% per year).
Operating margin has expanded, at 19.6% in the latest year.
Free cash flow has grown 31.2% per year over the past 5 years.
Financial health
Total debt has grown slower than revenue (-18.9% vs 19.3% per year).
Operating income covered interest expense 50× in the latest year.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
2025
$4.7B
$836M
60.1%
19.6%
30.5%
13.2%
$1.1B
—
$918M
2024
$4.0B
$576M
60.5%
14.9%
27.4%
8.9%
$631M
—
$606M
2023
$3.6B
$542M
63.2%
16.5%
26.2%
8.6%
$512M
—
$566M
2022
$2.9B
$341M
64.7%
13.4%
16.0%
6.3%
$305M
—
$642M
2021
$2.4B
$217M
68.6%
10.9%
10.6%
4.4%
$53M
—
$1.1B
2020
$1.9B
$550M
66.4%
15.5%
35.4%
12.8%
$277M
—
$818M
2019
$1.5B
$101M
63.1%
9.6%
11.5%
4.2%
$135M
—
$446M
2018
$1.0B
-$127M
64.4%
-18.1%
-19.2%
-6.6%
$56M
—
$1.1B
2017
$719M
-$50M
68.5%
-5.9%
—
-5.6%
$26M
—
$442M
2016
$573M
-$66M
66.0%
-11.1%
—
-16.3%
$500000
—
$95M
2015
—
-$58M
—
—
—
-19.7%
$16M
—
$86M
2014
—
-$22M
—
—
—
-12.1%
$7M
$5M
$72M
2013
—
-$30M
—
—
—
-24.3%
-$6M
$7M
$43M
2012
—
-$55M
—
—
—
-51.4%
-$43M
$7M
$8M
2011
—
-$45M
—
—
—
-37.1%
-$38M
—
$3M
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
Sep '26
$1.3B
$275M
64.3%
24.3%
10.9%
4.4%
$273M
—
$961M
Jun '26
$1.3B
$249M
63.4%
24.3%
9.5%
3.9%
$185M
—
$1.1B
Mar '26
$1.2B
$200M
62.9%
21.4%
6.7%
3.0%
$449M
—
$1.1B
Dec '25
$1.3B
$267M
62.9%
25.6%
9.7%
4.2%
$192M
—
$918M
Sep '25
$1.2B
$284M
60.5%
20.1%
10.4%
3.8%
$579M
—
$1.8B
Jun '25
$1.2B
$180M
59.5%
18.4%
7.0%
2.5%
$209M
—
$1.2B
Mar '25
$1.0B
$105M
56.9%
12.9%
4.7%
1.6%
$97M
—
$905M
Dec '24
$1.1B
$152M
58.9%
17.0%
7.2%
2.3%
$177M
—
$606M
Sep '24
$994M
$135M
59.7%
15.3%
6.8%
2.1%
$88M
—
$621M
Jun '24
$1.0B
$144M
62.4%
15.7%
5.9%
2.1%
$213M
—
$939M
Mar '24
$921M
$146M
61.0%
11.0%
6.5%
2.3%
$152M
—
$851M
Dec '23
$1.0B
$256M
63.5%
21.0%
12.4%
4.1%
$81M
—
$566M
Sep '23
$975M
$121M
63.9%
21.1%
5.3%
1.8%
$219M
—
$644M
Jun '23
$871M
$116M
62.7%
14.7%
5.5%
1.7%
$131M
—
$1.2B
Mar '23
$742M
$49M
62.4%
6.4%
2.2%
0.9%
$81M
—
$623M
Dec '22
$815M
$92M
66.4%
15.4%
4.3%
1.7%
$69M
—
$642M
Sep '22
$770M
$101M
64.2%
19.2%
5.5%
2.1%
$185M
—
$698M
Jun '22
$696M
$51M
64.6%
11.1%
2.3%
1.0%
$81M
—
$735M
Mar '22
$629M
$97M
63.3%
6.6%
4.4%
1.9%
-$31M
—
$716M
Dec '21
$698M
-$5M
67.7%
0.1%
-0.3%
-0.1%
$26M
—
$1.1B
Valuation over time
How the market has priced DXCM against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has fallen from 127.0× (Mar '23) to 37.8× (Nov '26).
The price-to-sales ratio has fallen from 14.9× (Mar '23) to 6.8× (Nov '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Frequently asked questions
Is DXCM growing its revenue and profit?
Over the past 5 years, DexCom's revenue has grown 19.3% per year, and net income grown 8.8% per year. These are computed facts, not advice.
How much debt does DXCM have?
As of FY2025, DexCom reported — of total debt against $918M of cash; operating income covered interest expense 50×.
What is DXCM's profit margin?
In FY2025, gross margin was 60.1%, operating margin 19.6%, and net margin 17.9%.
What is DXCM's P/E ratio?
DexCom's P/E (TTM) is 31.90 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the DXCM stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 37.8× as of Nov '26) can differ. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.